Floatz logo

cgx1321

Bile Duct Carcinoma

Curegenix Inc.Phase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

15 Active assets in the Bile Duct Carcinoma cohort.

Asset / SponsorPhaseRating
Capecitabine
University of Washington
Phase 1CC
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 1CC
Elimusertib
National Cancer Institute (NCI)
Phase 1CC
Ropidoxuridine
National Cancer Institute (NCI)
Phase 1CC
177lu-dota-sna040
SmartNuclide Biopharma
Early Phase 1C

View all 16 →

Same molecule, other indications

cgx1321 is also rated in:

digestive system cancerDormant
CC
Indicative ·
43 / 100
View asset →
carcinoma of esophagusDormant
CC
Indicative ·
41 / 100
View asset →
colorectal adenocarcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →